Filter By Category
Archives
Share on -
DALZANEMDOR
Generic Name: DALZANEMDOR
ABSTRACT -
Dalzanemdor (SAGE-718) is an investigational N-methyl-D-aspartate receptor positive allosteric modulator being evaluated for cognitive impairment associated with neurological disorders. It is not a prescribing guide.
DOSAGE -
- No routine clinical dosage is established for general use.
- Clinical-trial dose, route, titration, and stopping rules must be followed exactly.
- Avoid non-protocol use because neuropsychiatric and cognitive safety data remain under evaluation.
SIDE EEFECTS -
- Headache, dizziness, nausea, fatigue, somnolence, or insomnia may occur.
- Mood, cognition, balance, or neurologic symptoms should be monitored.
- Laboratory or vital-sign abnormalities may occur in early-phase studies.
ALLERGIC REACTIONS -
- Immediate rash, hives, itching, flushing, or generalized skin reaction
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, shortness of breath, or severe dizziness
- Severe hypotension, collapse, or anaphylaxis requires emergency care
- Any suspected allergy should be documented and reported to future healthcare providers
DRUG INTERACTIONS-
- Caution with CNS depressants, alcohol, sedatives, sleep medicines, and other neuroactive drugs.
- Concomitant drugs affecting cognition, seizure threshold, or balance may confound safety assessment.
- Patients should report all medicines and supplements.
PREAUTONS–
- Assess neurologic, psychiatric, pregnancy, hepatic, and renal status before use.
- Avoid driving or hazardous activity if dizziness, somnolence, or impaired attention occurs.
- Use only under clinical-trial or specialist supervision.
WARNINGS –
- New or worsening confusion, mood change, syncope, seizure, or severe allergic symptoms require urgent evaluation.
- Investigational efficacy and safety are not fully established.
- Keep out of reach of children.
Share on -
. Developed by